autologous AdHER2 dendritic cell vaccine

The autologous AdHER2 dendritic cell vaccine is an investigational personalized cancer immunotherapy designed to target tumors expressing the human epidermal growth factor receptor 2 (HER2). The therapy involves isolating a patient’s own mononuclear cells via apheresis and generating dendritic cells (DCs) that are then transduced ex vivo with an adenoviral vector encoding the extracellular and transmembrane domains of human HER2 (AdHER2). These modified DCs are administered back to the patient as a therapeutic vaccine. The mechanism of action centers on stimulating both humoral and cellular immune responses against HER2-positive tumor cells. Preclinical studies demonstrated antibody-mediated inhibition of tumor growth independent of Fc receptor function. Clinical trials have shown evidence of immunogenicity, safety, and preliminary clinical benefit in patients with various advanced or metastatic HER2-expressing cancers[1][8][6]. The product is manufactured under Good Manufacturing Practice regulations at specialized centers such as the NIH Clinical Center[1][6]. Primary indications under investigation include metastatic solid tumors with HER2 expression—including breast, ovarian, stomach/colon, bladder, and endometrial cancers—especially in patients who have progressed after standard therapies[1][4][6].

Other names

HER2-pulsed autologous dendritic cell vaccineHER-2-pulsed autologous dendritic cell vaccineHER 2-pulsed autologous dendritic cell vaccineHER2-pulsed type-1 polarized autologous dendritic cell vaccineHER-2-pulsed type-1 polarized autologous dendritic cell vaccineHER 2-pulsed type-1 polarized autologous dendritic cell vaccine